Vascular occlusion in hyaluronic acid filler is the iatrogenic interruption of arterial flow caused by intravascular product or compressive bolus. UK practitioners are expected to recognise it within minutes, treat it with high-dose pulsed hyaluronidase, and document every step against the JCCP and CPSA standards. This is the protocol the field expects in 2026.
What vascular occlusion actually is
A vascular adverse event from hyaluronic acid filler follows one of two clinical pathways. The first is direct intra-arterial embolisation, when product enters the lumen of a facial artery and travels distally until it lodges. The second is extrinsic compression, when a bolus volume sits hard against a vessel and chokes flow without ever entering it. Both end in tissue ischaemia. Both are emergencies.
The Complications in Medical Aesthetics Collaborative (CMAC) guideline, published in the Journal of Clinical and Aesthetic Dermatology, sets out the clinical anatomy practitioners are expected to know cold. The high-risk territories are the glabella, nasal dorsum and tip, nasolabial fold, lips, and infraorbital region, where the angular, dorsal nasal, supratrochlear, supraorbital and labial arteries run close to the injection plane.
Visual loss is the catastrophic end of the same pathway. Retrograde embolisation through the ophthalmic system can produce permanent blindness within minutes. The field treats this as the limit case, and it shapes the consent conversation upstream of the needle.
Recognition: the signs that matter in the chair
The CMAC guideline frames recognition around four signal categories. Practitioners working under the JCCP and CPSA Code of Practice are expected to assess all four during and immediately after any HA injection.
- Pain disproportionate to stimulus. Sudden escalating pain at the site or, more diagnostically, distal to the site is the earliest soft signal. Local anaesthetic can mask the very early window, which is why post-anaesthetic reassessment matters.
- Skin colour change. The CMAC paper sets out a five-stage progression: pallor or blanching first, then livedo reticularis (the mottled purple-reticulated pattern), then pustular change, then grey-black discoloration, then frank tissue necrosis with eschar or slough. The earliest stage is the only one with a real chance of full recovery.
- Capillary refill time. Normal CRT is under two seconds. Delayed CRT in the affected territory points to arterial compromise. Brisk CRT with bluish dusky skin can indicate venous compromise.
- Visual or neurological symptoms. Visual loss, ophthalmoplegia, ptosis, or any sudden neurological change is a same-minute escalation event. The intervention is hospital, not clinic.
Practitioners should be able to assess and document these signs in real time, in front of the patient. The mnemonic some courses teach (pain, pallor, paraesthesia, pulse, paralysis) is useful as a check, but the literature itself frames recognition around CRT and skin appearance.
Hyaluronidase: the pharmacology and the prescribing reality
Hyaluronidase is the only product with primary intervention status for HA filler vascular occlusion. The licensed UK product is Hyalase 1500 IU, a prescription-only medicine. Its Summary of Product Characteristics lists indications including enhancement of permeation of subcutaneous injections and the dispersal of extravasated fluids and blood. HA filler-induced vascular occlusion is not a licensed indication. Use in this context is off-label, and the standard of care in UK aesthetic practice rests on that off-label position being clinically defensible and properly documented.
The CMAC protocol is high-dose pulsed: 1,500 units reconstituted in approximately 1 ml of saline or lidocaine, infiltrated across the entire ischaemic territory along the course of the suspect vessel, with firm massage and warm compresses to promote diffusion. Capillary refill is reassessed at 60 minutes. The dose is repeated if the territory remains ischaemic, and the cycle continues until perfusion returns or the case is escalated to secondary care. The CMAC paper is explicit that extravascular injection is effective and that targeting the artery directly is unnecessary.
JCCP guidance on responsible prescribing is the second pillar. Hyalase is a POM. Only an appropriately qualified independent prescriber can supply it. Non-prescribing practitioners must have a documented arrangement, in advance, with a prescriber who can either authorise emergency supply or be physically present. A vascular occlusion is not the moment to start phoning around.
The escalation path
Some events outrun a clinic. A vascular occlusion that fails to reperfuse after repeated hyaluronidase, or any event with visual or neurological signs, is an emergency department referral. The clinic's role is to start hyaluronidase immediately, document, and call the patient through to the appropriate service without delay. The CMAC guideline notes the role of urgent ophthalmology referral for any visual signs and the role of plastic surgery or wound care for established necrosis.
The defensible position the regulator expects is that the practitioner identified the event, started treatment within minutes, escalated where appropriate, and documented every step contemporaneously. Compliance is assessed against the CPSA standards and the JCCP Code of Practice, not against an idealised guideline.
Documentation: what the regulator will read
Three documents matter, all signed and dated, all kept on file.
- Consent. The CPSA framework expects consent to address the specific risk of vascular occlusion, not just "rare side effects". The conversation should name the possibility, the recognition signs the patient should report, and the emergency protocol the clinic operates.
- Emergency protocol. A written, signed, in-clinic protocol that states which prescriber authorises the hyaluronidase, the stocked dose available, the escalation contact for ophthalmology and emergency care, and the post-event follow-up plan. The JCCP Code of Practice is the right reference for the standard.
- Contemporaneous notes. Time-stamped notes on recognition, dose given, response, repeat dose if needed, time of escalation. Photographs and short video of the affected territory are increasingly the field standard, with patient consent.
If you are working through scope, consent and the emergency protocols that the licensing scheme is going to expect, the RAG Pathway is the four-week programme designed to land practitioners aligned with JCCP, CPSA and MHRA standards before the regulations tighten. It covers complication frameworks alongside the broader compliance picture.
FAQ
Is hyaluronidase licensed in the UK for HA filler vascular occlusion?
No. The Hyalase 1500 IU SmPC lists permeation enhancement and resorption of extravasated fluids as the licensed indications. Use for HA filler-induced vascular occlusion is off-label. The CMAC guideline is the closest thing UK practice has to a consensus protocol for the off-label use.
Can a non-prescribing aesthetic practitioner hold hyalase on site?
A clinic can stock hyaluronidase, but supply to a patient must be authorised by an independent prescriber. JCCP guidance on prescribing is clear that the prescribing relationship and the supply route must be documented before treatment begins, not improvised during an event.
What is the high-dose pulsed protocol?
The CMAC protocol uses 1,500 units of hyaluronidase reconstituted in approximately 1 ml, infiltrated across the ischaemic territory along the suspect vessel. Capillary refill is reassessed at 60 minutes. The dose is repeated until perfusion returns or the case is escalated. The dilution and the volume are deliberately tight to avoid further compressive load on the tissue.
Does the patient need to be told about vascular occlusion specifically?
The CPSA competence framework and the JCCP Code of Practice treat informed consent as a process, not a form. For HA filler that means naming the specific risk of vascular occlusion, the recognition signs the patient should escalate, and the clinic's emergency protocol. A generic side-effects clause does not meet the standard.
What about visual loss?
Visual loss from retrograde ophthalmic embolisation is the worst-case end of the same pathway. The CMAC guideline treats it as a same-minute emergency, with immediate ophthalmology referral alongside hyaluronidase. The clinical literature is consistent that the window for any meaningful recovery is short, which is why the consent conversation upstream of high-risk territories carries real weight.
Where does this sit under the incoming licensing scheme?
The Health and Care Act 2022 licensing scheme is expected to bring HA filler under formal local-authority licensing, with the highest-risk procedures moving under the CQC. The complications framework, written protocols, prescribing arrangements and consent documentation, is the part of the scheme practitioners can lock in now without waiting for the secondary legislation to land.